Skip to content Skip to footer
Subscribe Now
Novo-Nordisk
NEWS

Novo Nordisk Reports the Health Canada’s Approval of Ozempic to Reduce Risk of Kidney Disease Progression & Cardiovascular Death in T2D & CKD Adults

Shots: Health Canada has approved Ozempic to reduce the risk of kidney disease worsening & CV death in adults with type 2 diabetes (T2D) & chronic kidney disease (CKD) Approval was based on P-IIIb (FLOW) trial assessing Ozempic (1mg, Q1W, n=1767) vs PBO (n=1766) in type 2 diabetes & CKD pts (N=3533) Study met its 1EP of 24% relative…
August 20, 2025

Read more

How to prevent chronic kidney disease
THOUGHTSPOT

How to prevent chronic kidney disease 

Chronic kidney disease is, in our opinion, one of the most underestimated health issues of all. Mainstream media usually discuss cancer and cardiovascular issues. However, did you know that only in the USA, around 35 million people are dealing with different types of kidney health issues? In other words, 1 in 7 US residents has…
June 4, 2025

Read more

Novo-Nordisk
NEWS

Novo Nordisk Reports the US FDA’s Approval for Ozempic to Reduce Risk of Kidney Disease Progression & Cardiovascular Death in Type 2 Diabetes & Chronic Kidney Disease (CKD) Adults

Shots: The US FDA has approved Ozempic to reduce the risk of kidney disease worsening & CV death in adults with type 2 diabetes & CKD Approval was based on P-IIIb (FLOW) trial assessing Ozempic (1mg, Q1W, n=1767) vs matching PBO (n=1766) in type 2 diabetes & CKD pts (N=3533) Study met its 1EP of 24% relative…
February 3, 2025

Read more

Viewpoints_Regina Fritsche-Danielson
VIEWPOINTS

AstraZeneca at ERA 2024: Regina Fritsche-Danielson in an Illuminating Dialogue Exchange with PharmaShots

Shots:  Associated with early onset and rapid progression of chronic kidney disease (CKD), APOL1 Mediated Kidney Disease dramatically affects people of African descent  AstraZeneca is developing AZD2373, the first potential precision treatment option for the treatment of AMKD with Ionis Pharmaceuticals. Recently, AZ shared promising data from the early P-I data from the MAD study …
August 26, 2024

Read more

Exclusive_Noelle Bush_2024
EXCLUSIVE

Noelle Bush in an Enlightening Interview with PharmaShots Shares Insights from the It Takes 2 Awareness Program

Shots:  Exemplifying awareness campaign at its best with a hint of contemporary music, “It takes 2” by Boehringer Ingelheim and Eli Lilly is a noble initiative aimed at integrating UACR testing with eGFR for better screening of CKD  Noelle Bush, in an engaging conversation with PharmaShots, cites the growing incidences of CKD in the US.…
January 15, 2024

Read more

VIEWPOINTS_Mohamed Eid_2023
VIEWPOINTS

Unlocking Approval: Mohamed Eid Dives into the Exciting Approval of Jardiance for Adult CKD Treatment in a Captivating Chat with PharmaShots

Shots:  Mohamed Eid, VP of Clinical Development & Medical Affairs, Cardio-Renal-Metabolism & Respiratory Medicine, at Boehringer Ingelheim, in a stimulating conversation with PharmaShots sheds light on the recent approval of Jardiance for the treatment of adults with chronic kidney disease   Jardiance’s EMPA Kidney P-III trial results demonstrated a 28% relative risk reduction vs placebo. Jardiance…
December 5, 2023

Read more

Load more